Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo <i>MET</i> Amplification in Patients with Metastatic <i>EGFR</i>-Mutated NSCLC

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo <i>MET</i> Amplification in Patients with Metastatic <i>EGFR</i>-Mutated NSCLC

Amplification of the <i>mesenchymal epithelial transition</i> (<i>MET</i>) gene is a mechanism of acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine-kinase-inhibitors (TKIs) in over 20% of patients with advanced <i>EGFR</i>-mutated (<i>E...

Full description

Bibliographic Details
Main Authors: Edyta M. Urbanska, Morten Grauslund, Peter R. Koffeldt, Sarah L. B. Truelsen, Johan O. Löfgren, Junia C. Costa, Linea C. Melchior, Jens B. Sørensen, Eric Santoni-Rugiu
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:International Journal of Molecular Sciences
Subjects:
<i>EGFR</i>-mutated NSCLC
EGFR-TKI
acquired <i>MET</i> amplification
de novo <i>MET</i> amplification
Crizotinib
combined targeted therapy
Online Access:https://www.mdpi.com/1422-0067/24/17/13077

Internet

https://www.mdpi.com/1422-0067/24/17/13077

Similar Items